Table 8 Results from the scenario analyses of PHiD-CV vaccination program vs. PCV13 in Taiwan
Parameter | Base-case | Scenario analysis | Cost (millions) | QALY | ICER |
|---|---|---|---|---|---|
Efficacy of PHiD-CV against 19A IPD | 71% | 19% | − 5.9 | 14 | Dominant (cost saving) |
Efficacy of PCV13 against ST3 IPD | 0% | 26% | − 8.8 | 21 | Dominant (cost saving) |
AOM inpatient IR reduced by 50% (2–9 years old) [per 100,000] | 1 year: 1011.3; 2 year: 1026.1; 3 year: 826.2 4 year: 795.8; 5 year: 245.8 | 1 year: 505.7; 2 year: 513; 3 year: 413.1; 4 year: 397.9; 5 year: 122.9 | − 4.8 | 20 | Dominant (cost saving) |
% of AOM cases caused by S. pneumoniae vs. NTHi | 35.9 (S. pneumoniae); 32.3 (NTHi) [55] | 55.7 (S. pneumoniae); 22.9 (NTHi) [59] | − 1.2 | 5 | Dominant (cost saving) |
Efficacy against pneumonia | PHiD-CV: 23.4% | PHiD-CV: 23.4% | − 9.3 | 22 | Dominant (cost saving) |
PCV13: 23.7% | PCV13: 23.4% | ||||
Efficacy of PCV13 against NTHi AOM reduced to −11% | 0% | −11% | − 19.6 | 39 | Dominant (cost saving) |
Efficacy of PHiD-CV against NTHi AOM reduced to 0 | 21.5% | 0% | 5.5 | − 12 | Dominated |
Time horizon | 10 years | Life time | − 8.8 | 16 | Dominant (cost saving) |
Price of vaccines (for illustration only) | Both priced at 1269.5 NTD/dose | PHiD-CV reduced by 10% (1142.5 NTD/dose) | − 90.4 | 21 | Dominant (cost saving) |